EMERGENT BIOSOLUTIONS INC. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$743M
Cost of Revenue
$326M
Gross Profit
—
R&D
$53M
SG&A
$186M
D&A
$96M
Operating Income
$100M
EBITDA
$196M
Interest Expense
$59M
Interest Income
—
Other Income/Expense
$42M
Pretax Income
$83M
Tax Provision
$30M
Net Income
$53M
Gross Margin
—
Operating Margin
13.5%
Net Margin
7.1%
Effective Tax Rate
36.5%
Deferred Tax Assets
$13M
Deferred Tax Liabilities
$38M
DTA Valuation Allowance
$330M
Tax Credit Carryforwards
$23M
NOL Carryforwards
$115M
ETR (Continuing Operations)
36.5%
ETR Federal Statutory
21.0%
Operating Lease Cost
—
Pension Net Periodic Cost
$0
Revenue YoY Variation
-28.8%
Income YoY Variation
192.1%